Drug intelligence / Profile preview

1-methyl ethyl 1-chloro-5-[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate

Development stage: Unknown
Modality: Small Molecules

Overview

This compound is an experimental small molecule belonging to the class of acylaminobenzoic acid derivatives. Its chemical formula is C16H18ClNO4S and it has a molecular weight of approximately 355.8 g/mol. There are no approved indications or clinical trials reported for this compound as of now. The mechanism of action and therapeutic applications have not been described in available sources[1][2].

Other names: 1-methyl ethyl 1-chloro-5-[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate

Beyond the preview

Go deeper on 1-methyl ethyl 1-chloro-5-[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1-methyl ethyl 1-chloro-5-[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate.

Explore the full profile